이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

크론병의 중등도 수술 후 재발 관리: 치료 확대의 무작위 대조 시험, POMEROL 시험. (포메롤) (POMEROL)

Study type : A 30 months, multicentre, open-label strategic randomized controlled trial

Population : Chron's Disease (CD) patients with an i2 endoscopic postoperative recurrence in the year following ileocolonic resection (6-12months after ileocolonic resection).

Treatments :

Stratification at inclusion according to prophylactic therapy.

Patients randomized in 2 arms:

  • Status quo arm: if the patient received no prophylactic therapy, no treatment will be started; if the patient received a prophylactic therapy, the same will be continued at the same dose.
  • Therapy escalation arm: infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.

Main objective : To evaluate the proportion of CD patients without endoscopic postoperative recurrence (i0-i1) at 12 months in the arm receiving therapy escalation compared to status quo arm in patients having an i2 endoscopic postoperative recurrence 6-12months after ileocolonic anastomosis with restoration of faecal stream.

연구 개요

상세 설명

Number of patients : 360 patients in approximatively 25 sites in France.

Recruitement period : The trial duration for each patients will be 12 months from radomization (18 to 24 months from screening (ie : post-operatively))

Endpoints:

Primary endpoints: Proportion of patients with an i0-i1 modified Rutgeerts score at 12 months.

Secondary endpoints:

  • Proportion of patients with an i3-i4 modified Rutgeerts score at 12 months

  • Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months

  • Proportion of patients with an i0 modified Rutgeerts score at 12 months

  • PRO2 score at 12 months

  • Clinical postoperative recurrence within 12 months: average daily SF ≥ 3.5 and average daily AP score ≥ 1.5, AND

    • increased CRP compared to inclusion, at least + 10 mg/l
    • OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g
  • Surgical recurrence within 12 months: need for a new ileocolonic resection

  • Endoscopic dilatation within 12 months: need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy

  • Time to clinical postoperative recurrence

  • Serious adverse events

  • Quality of life: EQ5D-5L questionnaire

  • Work productivity: Work Productivity and Activity Impairment questionnaire

연구 유형

중재적

등록 (실제)

213

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Crohn's disease diagnosed according usual criteria
  • Bowel resection with ileocolonic anastomosis performed removing all inflammatory lesions
  • Postoperative endoscopy performed between 6 and 12 months after ileocolonic anastomosis reaching the neoterminal ileum (patients who underwent a two stage surgical procedure are also eligible if the endoscopic evaluation is performed 6-12 months after restoration of the fecal stream)
  • Moderate endoscopic postoperative recurrence classified i2 according to the Rutgeerts score at 6-12 months, validated by a blinded central reading

Exclusion Criteria:

  • Patients with an ostomy
  • Ulcerative colitis or IBD type unclassified
  • Ileorectal or ileal pouch-anal anastomosis
  • Symptoms defined as average daily SF ≥ 3.5 and average daily AP score ≥ 1.5 having started after a free interval without symptoms of at least one month after surgery
  • Patients with obstructive symptoms of CD defined by a CDOS > 4
  • Patients exposed to infliximab before index surgery with a primary non-response (no clinical effect after 2 infusions at the discretion of the treating gastroenterologist) or history of infusion reactions to infliximab or history of detectable anti-infliximab antibodies
  • Patients treated with biological therapy (except for intraocular injections) or an investigational medical product after index surgery
  • Patients having started thiopurines or methotrexate more than 6 weeks after ileocolonic anastomosis with restoration of the fecal stream
  • Patients in whom not all inflammatory lesions have been removed at index surgery
  • Patients with active perianal Crohn's disease
  • Patients with a contraindication to infliximab: cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer, active tuberculosis or untreated latent tuberculosis, moderate or severe heart failure, HIV or HBV infection (serology < 6 months), recent live vaccination (within 4 weeks of baseline)
  • Pregnant women
  • Patients under legal protection or unable to express their consent.
  • Patients not affiliated to a health insurance system.
  • Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: Status quo arm

If the patient received no prophylactic therapy after resection, no treatments will be started.

If the patient received a prophylactic therapy after resection, the same will be continued at the same dose.

Stratification 1 : No treatments

Stratification 2 : Immunosuppressors at same dose

실험적: Therapy escalation arm

Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.

Stratification 1: Infliximab-CT-P13

Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors

다른 이름들:
  • 램시마

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of patients with an i0-i1 modified Rutgeerts score at 12 months.
기간: Month12

Number of patients with an i0-i1 modified Rutgeerts score at 12 months.

Month12

2차 결과 측정

결과 측정
측정값 설명
기간
Number of patients with an i3-i4 modified Rutgeerts score at 12 months
기간: Month 12

Number of patients with an i3-i4 modified Rutgeerts score at 12 months

Month 12
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
기간: Month 12

Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months

Month 12
Proportion of patients with an i0 modified Rutgeerts score at 12 months
기간: Month 12

Proportion of patients with an i0 modified Rutgeerts score at 12 months

Month 12
Patient Reporting Outcome score at 12 months.
기간: Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12

Patient Reporting Outcome score at 12 months will be assessed for the evaluation of disease activity (clinical remission).

Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
Clinical postoperative recurrence
기간: Baseline, Month 4, Month 8, Month 12

Clinical postoperative recurrence within 12 months defined by : Average daily Stool Frequency ≥ 3.5 and average daily Abdominal Pain score ≥ 1.5, AND

  • increased CRP compared to inclusion, at least + 10 mg/l
  • OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g

Average daily Stool frequency, average daily Abdominal Pain score, CRP and Calprotectin feacal will be combined to report the clinical postoperative recurrence (this outcome is is expressed without units)

Baseline, Month 4, Month 8, Month 12
Surgical recurrence within 12 months
기간: Baseline, Month 4, Month 8, Month 12

Surgical recurrence within 12 months defined by need for a new ileocolonic resection. Proportion of surgical recurrence within 12 months

Baseline, Month 4, Month 8, Month 12
Endoscopic dilatation within 12 months
기간: Baseline, Month 4, Month 8, Month 12

Endoscopic dilatation within 12 months defined by a need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy Proportion of endoscopic dilatation within 12 months

Baseline, Month 4, Month 8, Month 12
Time to clinical postoperative recurrence will be assessed
기간: Baseline, Month 4, Month 8, Month 12

Time to clinical postoperative recurrence will be assessed

Baseline, Month 4, Month 8, Month 12
Serious adverse events
기간: Screening, Baseline, Month 4, Month 8, Month 12

Occurence of Serious Adverse Events

Screening, Baseline, Month 4, Month 8, Month 12
Quality of life: EQ5D-5L questionnaires
기간: Baseline, week 2, week 6, Month 4, Month 8, Month 12

Quality of life will be assessed with the EQ5D-5L questionnaire

Baseline, week 2, week 6, Month 4, Month 8, Month 12
Work productivity and activity impairement questionnaires
기간: Baseline, week 2, week 6, Month 4, Month 8, Month 12

Work productivity and activity impairement will be assessed with work productivity and activity impairement questionnaires

Baseline, week 2, week 6, Month 4, Month 8, Month 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 12월 21일

기본 완료 (실제)

2026년 10월 15일

연구 완료 (실제)

2026년 10월 15일

연구 등록 날짜

최초 제출

2021년 8월 18일

QC 기준을 충족하는 최초 제출

2021년 9월 28일

처음 게시됨 (실제)

2021년 10월 11일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다